Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Long-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study

Olga Elisyutina
* ,
Maria Byazrova
,
Alla Litovkina
,
Evgeniy Smolnikov
,
Daria Chernushevich
,
Maria Sukhova
,
Artem Mikhailov
,
Dmitry Kudlay
ORCID logo ,
Elena Fedenko
,
Nataliya Ilina
,
Alexander Filatov
ORCID logo ,
Musa Khaitov
Version 1 : Received: 23 October 2023 / Approved: 24 October 2023 / Online: 25 October 2023 (07:35:00 CEST)

How to cite: Elisyutina, O.; Byazrova, M.; Litovkina, A.; Smolnikov, E.; Chernushevich, D.; Sukhova, M.; Mikhailov, A.; Kudlay, D.; Fedenko, E.; Ilina, N.; Filatov, A.; Khaitov, M. Long-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study. Preprints 2023, 2023101584. https://doi.org/10.20944/preprints202310.1584.v1 Elisyutina, O.; Byazrova, M.; Litovkina, A.; Smolnikov, E.; Chernushevich, D.; Sukhova, M.; Mikhailov, A.; Kudlay, D.; Fedenko, E.; Ilina, N.; Filatov, A.; Khaitov, M. Long-Term Impact of Dupilumab Treatment on Systemic Cytokine Profile in Atopic Dermatitis Patients: A Cross-Sectional Study. Preprints 2023, 2023101584. https://doi.org/10.20944/preprints202310.1584.v1

Abstract

Atopic dermatitis (AD), a T2 inflammatory skin condition, is widely recognized as one of the most prevalent chronic and recurrent skin disorders. One of the most effective therapy for treating moderate-to-severe AD is Dupilumab, a monoclonal antibody that blocks both IL-4 and IL-13 signaling. At the same time, no comprehensive analysis of cytokines profile was made in AD patients undergoing Dupilumab therapy. The primary objective of our research was to examine the levels of main cytokines to better understanding systemic immune response in AD and to identify potential biomarkers of the effectiveness of Dupilumab treatment. AD patients demonstrated significant clinical improvements one year after initializing of Dupilumab therapy. We identified 16 cytokines that showed major difference between Dupilumab-treated patients and patients without Dupilumab therapy. Six cytokines showed correlation with AD severity and the efficacy of Dupilumab therapy. Jointly revealed cytokines could potentially predict the effectiveness of Dupilumab treatment and help to choose the precision target therapy in AD patients as well.

Keywords

Atopic dermatitis; cytokines profiling; Dupilumab; T2 immune response

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.